Top Tweets for #lupsma
Evaluating the impact of #RLT on clonal hematopoiesis #CHIP: our experience with #LuPSMA published in @JournalofNucMed @SNM_MI
https://t.co/aTprKRwarQ
@DanaFarber_GU @adamssperling @Lachelle_Dawn @HJacene @PCF_Science @urotoday 1/3
The pre-taxane #LuPSMA era is changing the mCRPC sequence 🧬
In a fit, BRCAwt patient with bone-only, PSMA-avid disease…
👉 Would you still start with docetaxel or radium-223, or move directly to Lu-PSMA?
Curious to hear how colleagues are sequencing this in practice 👇
#ProstateCancer #mCRPC #Theragnostics #GUonc #OncoTwitter #IUCS26
@ecancer @urotoday @UrologyTimes @OncoAlert @ONCOassist @OncLive
@neerajaiims
What are the outcomes of #LuPSMA in #octagenarians with advanced prostate cancer? Our collaborative experience with @DanaFarber_GU @MayoClinic @VUMChealth led by Daniel Sentana and Avina Rami, published in @JCOOP_ASCO: https://t.co/XTUZHpveD0
How are patients receiving #LuPSMA monitored during routine practice? Read our manuscript, led by @harvardmed student Narmeen Rashid, published in Clin Gen Cancers: @DanaFarber_GU @PCF_Science @urotoday @HJacene
https://t.co/8zkrKWujKL
Enhorabuena a los compañeros por sus magníficas ponencias y gracias a Novartis por invitarme a participar en este evento. Un placer poder compartir y debatir con vosotros. #teragnosis #LuPsma
Hoy ha tenido lugar la reunión de Castilla y León de Lanzamiento de Pluvicto organizada por Novartis con ponencias de los Oncólogos Médicos y Médicos Nucleares del Sacyl.
#cáncerdepróstata #teragnosis #Pluvicto #
Does #LuPSMA #Pluvicto have activity in PSMA+ve ccRCC? Protocol of our ongoing IIT published in @JournalofNucMed @HJacene @DrChoueiri @DanaFarber_GU @DanaFarberNews https://t.co/iXwzmraMxT
What if PET Imaging Could Help Predict Toxicity Risk under LuPSMA Therapy? - Jeremie Calais (@CalaisJeremie)
https://t.co/m42neJ5zbI
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #PersonalizedMedicine #Theranostics #PSMAPET #RLT #LuPSMA #NuclearMedicine #PETCT #PrecisionOncology
❓ What if PSMA PET could predict toxicity risk under LuPSMA therapy? 📷 In 61 patients, quantitative PSMA PET also predicted toxicity & side-effects.
https://t.co/0jZhgBHkcg
#PSMAPET #LuPSMA #RLT #Theranostics #PrecisionOncology #NuclearMedicine #PETCT #UCLA
Interesting study #SBRT+/-#LuPSMA @JCO_ASCO 👏🏼
⭐️Innovative design w/limited dosing of LuPSMA in #oligorecurrent #ProstateCancer
❓What if all pts were MTD-Naive
🤔Worth noting the significant differences in 🔑baseline characteristics
🤔PFS criterial have❓Clinical value
🌙LUNAR phase 2 RCT: adding Lu-177 PSMA to SABR for oligorecurrent prostate cancer significantly improved PFS without increased toxicity
Just out in @JCO_ASCO: https://t.co/3i8RwkJRy3
Impressive trial and results @AmarUKishan @CalaisJeremie and team
💫🌟📍#UromigosLIVE Nashville
💥 Radioligand therapy across disease stages , a sharp, brave and highly interactive discussion led by @brian_rini, @DrRanaMcKay, @ChrisSweens1 & Michael Morris MD.
🧩 Comparing #LuPSMA trials:
VISION 🔹 HR 0.40
PSMAfore 🔹 HR 0.49
PSMAaddition 🔹 HR 0.72
PR21 🔹 rPFS HR 1.01 – OS HR 1.64
💬 Clever, bold questions from the panel:
– What’s the right dose and timing for each intervention?
– How reliable is OS when cross-over blurs the signal?
– How do we interpret rPFS vs OS differences across lines of therapy?
– When should we introduce chemo vs lutetium?
🎯 Insight: Learning from these designs is key.
#PSMAaddition reminds us that a strong control arm and cross-over can reshape OS interpretation and highlight the real impact in clinical practice.
@Uromigos @tompowles1 @brian_rini @OncoAlert @lalaniMD @AmandaNizamMD @DrKarineTawagi @ReneeSaliby @NazliDizman @uromigosjapan @TresUramigas @weoncologist @neerajaiims @PGrivasMDPhD @montypal
#OncoAlertAF
@acampsmalea @BRicciutiMD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
#mHSPC #ProstateCancer #RadioligandTherapy #OncoAlert #UromigosLIVE #GUOncology
💫🌟📍#UromigosLIVE Nashville
💥 Radioligand Therapy in #mHSPC chaired by @brian_rini with @DrRanaMcKay, @ChrisSweens1 & Michael Morris MD.
The discussion was vibrant and multidimensional — a palette of perspectives on #LuPSMA in mHSPC 🎨
🔹 Rana McKay: “Still many open questions — patient selection, AE management, how many cycles are safe.” Optimistic yet pragmatic tone.
🔹 Michael Morris: “Early days — curve separation is promising, but we must stay realistic.”
🔹 Chris Sweeney: “Efficacy somewhat disappointing — more refinement needed before changing SOC.”
💭 Consensus: The scenario is promising but requires precise selection, longer follow-up, and balanced interpretation before declaring victory.
@Uromigos @tompowles1 @brian_rini @OncoAlert @lalaniMD @AmandaNizamMD @DrKarineTawagi @ReneeSaliby @NazliDizman @uromigosjapan @TresUramigas @weoncologist @neerajaiims @PGrivasMDPhD @montypal
#OncoAlertAF
@acampsmalea @BRicciutiMD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88
#mHSPC #ProstateCancer #RadioligandTherapy #OncoAlert #UromigosLIVE #GUOncology
💫🌟📍#UromigosLIVE Nashville
💥 Radioligand therapy a lo largo de la evolución del cáncer de próstata — debate valiente y brillante moderado por @brian_rini con @DrRanaMcKay, @ChrisSweens1 y Michael Morris MD.
📊 Comparando los principales estudios con #LuPSMA:
VISION 🔹 HR 0.40
PSMAfore 🔹 HR 0.49
PSMAaddition 🔹 HR 0.72
PR21 🔹 rPFS HR 1.01 – OS HR 1.64
💬 Preguntas clave del panel:
– ¿Cuál es la dosis y momento óptimo para cada intervención?
– ¿Qué tan fidedigna es la OS cuando el cross-over influye tanto?
– ¿Por qué la rPFS y la OS divergen según la línea de tratamiento?
– ¿Cuándo conviene quimio y cuándo Lutecio?
🎯 Mensaje: Aprender de estos diseños es esencial.
#PSMAaddition muestra cómo un brazo control fuerte y el crossover pueden alterar la interpretación de OS, desafiando la lectura clínica tradicional.
@Uromigos @tompowles1 @brian_rini @OncoAlert @lalaniMD @AmandaNizamMD @DrKarineTawagi @ReneeSaliby @NazliDizman @uromigosjapan @TresUramigas @weoncologist @neerajaiims @PGrivasMDPhD @montypal
#OncoAlertAF
@acampsmalea @BRicciutiMD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 #CáncerDePróstata #Radioligandos
#PSMA #mHSPC #mCRPC #OncoAlert #GUOncology
2/ 🎯 Background:
#LuPSMA is an approved radioligand therapy for mCRPC. However, reliable biomarkers to predict benefit and guide treatment decisions are lacking.
1/ 🚨 Pleased to share that our latest manuscript is out now in @EUplatinum!
Baseline and on-treatment #ctDNA biomarkers in men with advanced #ProstateCancer treated with #LuPSMA.
https://t.co/koAm8SgnK9
Thanks to @LouiseKostos Heidi Fettke @PeterMacCC
Such an Honor to discuss such hot topics with the amazing @dandanmena from @UroTeragLATAM
#ProstateCancer #PSMA #LuPSMA
Oncology: Here & Now is BACK‼️
Season 2 kicks off September 2nd, 2025
Topic: GU Oncology 🚨
Join @bavilima 🇧🇷& @dandanmena 🇲🇽 on this Great Webcast as they discuss:
✅Rationale between BULLSEYE🎯 Trial
✅Difference Between Lutetium & Terbium
✅Affinity🆚Toxicity
✅FU of patients with PSMA PET
and much much more...STAY TUNED!!
Ping
OncoAlert GU faculty
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen
@tompowles1 @BraunMDPhD @cdanicas @brian_rini
#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Abdallah81MD @FernandoOnco
@ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @BenWestphalen @NiuSanford
When should we use 18F-FDG PET?
Andrei Iagaru, MD @StanfordMed makes the case for FDG-PET in advanced #ProstateCancer 🔍
He argues it’s essential—not optional—for identifying aggressive PSMA-negative disease, optimizing #LuPSMA therapy, and explaining non-response despite meeting #VISION trial criteria.💡
#WatchNow on UroToday > https://t.co/wWYyxoBidw #PSMAandBeyond2025 #UroOnc #NuclearMedicine @PSMAconference
When should we use 18F-FDG PET?
Andrei Iagaru, MD @StanfordMed makes the case for FDG-PET in advanced #ProstateCancer 🔍
He argues it’s essential—not optional—for identifying aggressive PSMA-negative disease, optimizing #LuPSMA therapy, and explaining non-response despite meeting #VISION trial criteria.💡
#WatchNow on UroToday > https://t.co/wWYyxoBidw #PSMAandBeyond2025 #UroOnc #NuclearMedicine @PSMAconference
Does race impact outcomes to #LuPSMA? Pleased to share our multi-institutional retrospective study (N=650pts) looking at this Q published in Cancers: https://t.co/J55zI1zyjb
@DanaFarber_GU @HJacene @ThomasNgImaging
When should we use 18F-FDG PET?
Andrei Iagaru, MD @StanfordMed makes the case for FDG-PET in advanced #ProstateCancer 🔍
He argues it’s essential—not optional—for identifying aggressive PSMA-negative disease, optimizing #LuPSMA therapy, and explaining non-response despite meeting #VISION trial criteria.💡
#WatchNow on UroToday > https://t.co/wWYyxoBidw #PSMAandBeyond2025 #UroOnc #NuclearMedicine @PSMAconference
#ASCO25 great data from #India #DrSood #mHSPC escalation study adding #LuPSMA to patients not achieving good response to docetaxel @neerajaiims @DrYukselUrun
Last Seen Hashtags on Sotwe
momson filter:native_video
Seen from United Kingdom
TejRan
Seen from Turkey
ometv
Seen from Portugal
momcest
Seen from Mexico
mom #ipcam() + filter:native_video
Seen from Japan
นัดเย็ดเกาะเสม็ด
Seen from Thailand
diyarbakırgay
Seen from Turkey
smno #ipcam #brosis #candid (*)+ filter:native_video
Seen from United States
ipcam filter:native_video
Seen from United States
omegle
Seen from United Kingdom
Most Popular Users
Elon Musk 
@elonmusk
241.6M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.9M followers
Taylor Swift
@taylorswift13
83.8M followers
Lady Gaga
@ladygaga
75.3M followers
Virat Kohli
@imvkohli
73.2M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.2M followers
Bill Gates
@billgates
65M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers